| 臺大學術典藏 |
2020-10-20T05:50:00Z |
Structural markers observed with endoscopic 3-dimensional optical coherence tomography correlating with Barrett's esophagus radiofrequency ablation treatment response (with videos)
|
Kirtane T.; Figueiredo M.; Ahsen O.O.; ������; Tao Y.K.; Zhou C.; Tsai T.-H.; Mashimo H.; Fujimoto J.G.; Huang Q.; Schmitt J.M.; Adler D.C.; Kirtane T.; Figueiredo M.; Ahsen O.O.; Tao Y.K.; HSIANG-CHIEH LEE; Tsai T.-H.; Zhou C.; Adler D.C.; Schmitt J.M.; Huang Q.; Fujimoto J.G.; Mashimo H.; HSIANG-CHIEH LEE |
| 臺大學術典藏 |
2020-10-20T05:49:58Z |
OCM image texture analysis for tissue classification
|
HSIANG-CHIEH LEE; Zhou C.; Huang X.; Fujimoto J.G.; ������; wan S.; Zhou C.; Huang X.; wan S.;HSIANG-CHIEH LEE;Fujimoto J.G.;Huang X.;Zhou C.; wan S.; HSIANG-CHIEH LEE; Fujimoto J.G. |
| 臺大學術典藏 |
2020-10-20T05:49:56Z |
Optical coherence microscopy
|
Fujimoto J.G.; HSIANG-CHIEH LEE; Ahsen O.O.; ������; Zhou C.; Aguirre A.D.; Ahsen O.O.; Fujimoto J.G.; HSIANG-CHIEH LEE; Zhou C.; Aguirre A.D.; Aguirre A.D.;Zhou C.;HSIANG-CHIEH LEE;Ahsen O.O.;Fujimoto J.G.Aguirre A.D.;Zhou C.;HSIANG-CHIEH LEE;Ahsen O.O.;Fujimoto J.G. |
| 臺大學術典藏 |
2020-10-20T05:49:56Z |
Spoke-LBP and ring-LBP: New texture features for tissue classification
|
Wan S.;Huang X.;HSIANG-CHIEH LEE;Fujimoto J.G.;Zhou C.; Wan S.; Huang X.; HSIANG-CHIEH LEE; Fujimoto J.G.; Zhou C.; Wan S.; Huang X.; ������; Fujimoto J.G.; Zhou C.; HSIANG-CHIEH LEE |
| 臺大學術典藏 |
2020-10-20T05:49:55Z |
Integrated local binary pattern texture features for classification of breast tissue imaged by optical coherence microscopy
|
Wan S.; ������; Huang X.; Xu T.; Xu T.; Zeng X.; Zhang Z.; Sheikine Y.; Connolly J.L.; Fujimoto J.G.; Zhou C.; HSIANG-CHIEH LEE; Zhou C.; Fujimoto J.G.; Connolly J.L.; Zhang Z.; Sheikine Y.; Xu T.; Zeng X.; Xu T.; Huang X.; HSIANG-CHIEH LEE; Wan S.; Wan S.;HSIANG-CHIEH LEE;Huang X.;Xu T.;Xu T.;Zeng X.;Zhang Z.;Sheikine Y.;Connolly J.L.;Fujimoto J.G.;Zhou C. |
| 臺大學術典藏 |
2020-08-12T06:34:46Z |
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
|
Mok T.;Wu Y.-L.;Lee J.S.;Chong-Jen Yu;Sriuranpong V.;Sandoval-Tan J.;Ladrera G.;Thongprasert S.;Srimuninnimit V.;Liao M.;Zhu Y.;Zhou C.;Fuerte F.;Margono B.;Wen W.;Tsai J.;Truman M.;Klughammer B.;Shames D.S.;Wu L.; Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. |
| 臺大學術典藏 |
2020-07-10T08:16:04Z |
Internal networking and organisational capability: Towards a new perspective of the firm
|
Tsai, T.; Zhou, C.; Cheng, B.; BOR-SHIUAN CHENG |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
CHIH-HSIN YANG; Sequist L.V; Geater S.L; Tsai C.-M; Mok T.S.K; Schuler M; Yamamoto N; Yu C.-J; Ou S.H.I; Zhou C; Massey D; Zazulina V; Wu Y.-L.; Wu Y.-L.;Zazulina V;Massey D;Zhou C;Ou S.H.I;Yu C.-J;Yamamoto N;Schuler M;Mok T.S.K;Tsai C.-M;Geater S.L;Sequist L.V;Chih-Hsin Yang |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
